Introduction {#S1}
============

The NOD2 protein plays an important role in the function of the immune system. It is active in certain types of immune system cells, including monocytes, macrophages, and dendritic cells, which help to protect the body against foreign invaders, such as viruses and bacteria \[[@ref1]\]. NOD2 also regulates the activity of genes that control immune responses and inflammatory reactions, and plays a role in a process called autophagy \[[@ref3]\]. The gene that encodes this protein is located on 16q12.1 \[[@ref2]\].

The *NOD2* 3020insC allele is reported in \~7.3% of the Polish population \[[@ref4]\]. In the literature, the presence of *NOD2* mutation is associated with increased risk of breast cancer (BC) before the age of 50 years (\~1%) \[[@ref5]\]. This mutation occurs in \~8% of all BC and increases the risk of DCIS in those aged \< 50 years by five times. The presence of the *NOD2* 3020insC allele also increases the lifetime risk of colorectal cancer at the age of over 60 years (by over 2-fold), lung cancer (\~2-fold), and ovarian cancer (\~1.5-fold) \[[@ref6], [@ref9]\]. The 3020insC mutation of the *NOD2*/*CARD15* gene may also be a genetic predisposing factor for aggregations of breast and lung cancer \[[@ref11]\].

In the literature, there are only a few data describing the association between the presence of *NOD2* mutation and clinicopathological factors. The associated factors confirmed in the aforementioned studies were younger age at diagnosis, family history of cancer (especially breast and gastrointestinal cancer) \[[@ref8]\], and early-stage disease \[[@ref6]\]. In our previous study, the presence of *NOD2* (3020insC) in women with BC was characterised by positive predictive factors such as: lymph nodes without metastasis (N0), lower histological grade (G\<3), and negative HER2 receptor status (HER2--) \[[@ref7]\].

The purpose of the present study was to characterise BC *NOD2*-mutation carriers at age ≥ 50 years, according to clinicopathological factors or family history. Patients aged ≥ 50 years were compared with the control group and with *NOD2*-mutation carriers at age \< 50 years.

Material and methods {#S2}
====================

The analysed group were divided into two subgroups according to patient age: 1) \< 50 years; and 2) ≥ 50 years. The clinicopathological factors were analysed, as well as the presence of cancer in family history in younger (age, \< 50 years) (45.3%, *n* = 68/150) and in older (age, ≥ 50 years) (54.7%, *n* = 82/150) patients with BC with confirmed *NOD2* (c.3020insC) mutation (GenBank NM \_022162.1). Control groups were selected from patients with BC who tested negative for the mutations (37.5% \< 50 years, *n* = 141; 62.5% ≥ 50 years; *n* = 235/376). The presence of the most common mutations in *BRCA1* (c.68_69delAG, c.181T\>G, c.4034delA, c.5266dupC, c.3700_3704del5) (GenBank NM_007294.3), *BRCA2* (c.5946delT and c.9403delC) (GenBank NM_000059.3), and CHEK2\*1100delC or I157T (GenBank NM_007194.3) genes were excluded. Mutation analysis was carried out by a multiplex allele-specific PCR assay. Genetic diagnostics were conducted between the years 2012 and 2018. All patients gave written, informed consent for genetic examination.

All patients were females who were diagnosed, treated, and followed-up at the National Research Institute of Oncology in Gliwice. Patients underwent clinical follow-up examinations every three months in the first two years, every six months afterwards until the fifth year after diagnosis, and every year subsequently. The inclusion criteria were: BC confirmed by microscopic examination; performance status ZUBROD 0--1; age above 18 years; the normal levels of renal and liver function and normal values of bone marrow. The data of age at onset, menopausal status, surgical procedure, disease stage according to TNM classification, histology, oestrogen (ER) and progesterone receptor (PR) status, HER2 status, and contralateral BC were gathered from hospital records and pathology reports. The analysis of patient medical records was performed according to national law regulation.

The median age at diagnosis of all patients was 52.4 years (range, 25.5--80.7 years). Patient clinicopathological characteristics are presented in [Table 1](#T1){ref-type="table"}. A total of 209 patients were at the age \< 50 years and 317 at the age ≥ 50 years. All patients had good performance status (ZUBROD 0--1). The complete characteristics of patients with regards to demographic and clinicopathological features are presented in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}.

###### 

Clinicopathological characteristics of all study group breast cancer patients (*n* = 526)

  Risk factor              Breast cancer                   
  ------------------------ ------------------------- ----- ------
  Age median (range)       52.4 years (25.5--80.7)         
  Clinical staging nodes                                   
                           N positive                226   43.0
                           N negative                300   57.0
  Tumour size                                              
                           T3--4                     83    15.8
                           T1--2                     443   84.2
  Grade G                                                  
                           G3                        161   30.6
                           G1+G2                     365   69.4
  ER                                                       
                           Negative                  159   30.2
                           Positive                  367   69.8
  PR                                                       
                           Negative                  196   37.3
                           Positive                  330   62.7
  HER2 overexpression                                      
                           Positive                  215   40.9
                           Negative                  311   59.1
  Molecular subtype                                        
                           Luminal A & B-- type      236   44.9
                           Others                    290   55.1
  Triple negative                                          
                           Yes                       75    14.3
                           No                        451   85.7
  Histological type                                        
                           Ductal invasive           401   76.2
                           Lobular invasive ca       52    9.9
                           Other                     73    13.9
  Molecular subtype                                        
                           Luminal A type            102   19.4
                           Luminal B-- type          134   25.5
                           Luminal B+ type           143   27.2
                           Triple negative           75    14.3
                           Non luminal               72    13.7

###### 

Clinical characteristics of breast cancer patients according to age

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Risk factor                               *NOD2*\                   Control group\            OR     *p*         *NOD2* ≥ 50 years\        Control group ≥ 50 years\   OR      *p*                                    
                                            \< 50 years\              \< 50 years\                                 (*n* = 82)                (*n* = 235)                                                                
                                            (*n* = 68)                (*n* = 141)                                                                                                                                       
  ----------------------------------------- ------------------------- ------------------------- ------ ----------- ------------------------- --------------------------- ------- ----------- ------ ----- ------ ------ -------
  Age median (range)                        42.8 years (25.5--49.9)   43.8 years (26.4--50.0)          0.331^\*^   58.2 years (50.0--80.7)   59.3 years (50.0--78.3)             0.928^\*^                              

  Menopausal status                                                                                                                                                                                                     

                                            Premenopausal             61                        89.7   129         91.5                      0.81                        0.798   13          15.9   31    13.2   1.24   0.678

                                            Postmenopausal            7                         10.3   12          8.5                       1.0                                 69          83.1   204   86.8   1.0    

  Co-morbid condition                                                                                                                                                                                                   

                                            Yes                       17                        25.0   46          32.6                      0.69                        0.335   53          64.6   139   59.1   1.26   0.457

                                            No                        51                        75.0   95          67.4                      1.0                                 29          35.4   96    40.9   1.0    

  Diabetes                                                                                                                                                                                                              

                                            Yes                       2                         2.9    2           1.4                       2.11                        0.597   4           4.9    13    5.5    0.88   1.00

                                            No                        66                        97.1   139         98.6                      1.0                                 78          95.1   222   94.5   1.0    

  Cardiovascular diseases                                                                                                                                                                                               

                                            Yes                       2                         2.9    1           0.7                       4.24                        0.248   9           11.0   38    16.2   0.64   0.284

                                            No                        66                        97.1   140         99.3                      1.0                                 73          89.0   197   83.8   1.0    

  Viral diseases                                                                                                                                                                                                        

                                            Yes                       0                         0.0    5           3.5                       0.0                         0.176   3           3.7    13    5.5    0.65   0.770

                                            No                        68                        100    136         96.5                      1.0                                 79          96.3   222   94.5   1.0    

  Cancer in family history                                                                                                                                                                                              

                                            Yes                       41                        60.3   83          58.9                      1.06                        0.963   53          64.6   123   52.3   1.66   0.072

                                            No                        27                        39.7   58          41.1                      1.0                                 29          35.4   112   47.7   1.0    

  Breast cancer in family history                                                                                                                                                                                       

                                            Yes                       17                        25.0   27          19.1                      1.41                        0.429   26          31.7   35    14.9   2.65   0.002

                                            No                        51                        75.0   114         80.9                      1.0                                 56          68.3   200   85.1   1.0    

  Lung cancer in family history                                                                                                                                                                                         

                                            Yes                       6                         8.8    13          9.2                       0.95                        0.870   6           7.3    21    8.9    0.80   0.819

                                            No                        62                        91.2   128         90.8                      1.0                                 76          92.7   214   91.1   1.0    

  Gynaecological cancer in family history                                                                                                                                                                               

                                            Yes                       7                         10.3   12          8.5                       1.23                        0.870   10          12.2   25    10.6   1.17   0.855

                                            No                        61                        89.7   129         91.5                      1.0                                 72          87.8   210   89.4   1.0    

  Stomach cancer in family history                                                                                                                                                                                      

                                            Yes                       6                         8.8    12          8.5                       1.04                        0.851   8           9.8    14    6.0    1.71   0.361

                                            No                        62                        91.2   129         91.5                      1.0                                 74          90.2   221   94.0   1.0    

  Pancreas cancer in family history                                                                                                                                                                                     

                                            Yes                       4                         5.9    2           1.4                       4.34                        0.089   2           2.4    4     1.7    1.44   0.651

                                            No                        64                        94.1   139         98.6                      1.0                                 80          97.6   231   98.3   1.0    

  Bowel cancer                                                                                                                                                                                                          

                                            Yes                       10                        14.7   8           5.7                       2.87                        0.037   9           11.0   25    10.6   1.04   0.903

                                            No                        58                        85.3   133         94.3                      1.0                                 73          89.0   210   89.4   1.0    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mann-Whitney U test

###### 

Pathological characteristics of the tumours in breast cancer patients according to age

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Risk factor              *NOD2* \< 50 years\    Control group \< 50 years\   OR     *p*   *NOD2* ≥ 50 years\   Control group ≥ 50 years\   OR       *p*                              
                           (*n* = 68)             (*n* = 141)                               (*n* = 82)           (*n* = 235)                                                           
  ------------------------ ---------------------- ---------------------------- ------ ----- -------------------- --------------------------- -------- ----- ------ ----- ------ ------ --------
  Clinical staging nodes                                                                                                                                                               

                           N positive             25                           36.8   75    53.2                 1                           0.038    27    32.9   99    42.1   1      0.182

                           N negative             43                           63.2   66    46.8                 1.95                                 55    67.1   136   57.9   1.48   

  Tumour size                                                                                                                                                                          

                           T3--4                  11                           16.2   25    17.7                 1                           0.934    5     6.1    42    17.9   1      0.011

                           T1--2                  57                           83.8   116   82.3                 1.12                                 77    93.9   193   82.1   3.35   

  Grade G                                                                                                                                                                              

                           G3                     27                           39.7   50    35.5                 1.20                        0.658    14    17.1   70    29.8   0.49   0.036

                           G1 + G2                41                           60.3   91    64.5                 1                                    68    82.9   165   70.2   1      

  ER                                                                                                                                                                                   

                           Negative               16                           23.5   54    38.3                 0.50                        0.049    13    15.9   76    32.3   0.39   0.007

                           Positive               52                           76.5   87    61.7                 1                                    69    84.1   159   67.7   1      

  PR                                                                                                                                                                                   

                           Negative               21                           30.9   56    39.7                 0.68                        0.277    19    23.2   100   42.6   0.41   0.003

                           Positive               47                           69.1   85    60.3                 1                                    63    76.8   135   57.4   1      

  HER2 overexpression                                                                                                                                                                  

                           Positive               15                           22.1   76    53.9                 0.24                        0.0001   8     9.8    116   49.4   0.11   0.0001

                           Negative               53                           77.9   65    46.1                 1                                    74    90.2   119   50.6   1      

  Molecular subtype                                                                                                                                                                    

                           Luminal A & B-- type   41                           60.3   42    29.8                 3.58                        0.0001   64    78.0   89    37.9   5.83   0.0001

                           Others                 27                           39.7   99    70.2                 1                                    18    22.0   146   62.1   1      

  Triple negative                                                                                                                                                                      

                           Yes                    12                           17.6   23    16.3                 1.10                        0.965    10    12.2   30    12.8   0.95   0.953

                           No                     56                           82.4   118   83.7                 1                                    72    87.8   205   87.2   1      

  Histological type                                                                                                                                                                    

                           Ductal invasive        54                           79.4   110   78.0                 1                                    61    74.4   176   74.9   1      

                           Lobular invasive ca    7                            10.3   12    8.5                  1.19                        0.932    8     9.8    25    10.6   0.92   0.977

                           Other                  7                            10.3   19    13.5                 0.75                        0.702    13    15.8   34    14.5   1.10   0.926

  Molecular subtype                                                                                                                                                                    

                           Luminal A type         18                           26.5   10    7.1                  1                                    40    48.8   34    14.5   1      

                           Luminal B-- type       23                           33.8   32    22.7                 0.40                        0.0885   24    29.3   55    23.4   0.37   0.005

                           Luminal B+ type        11                           16.2   48    34.0                 0.13                        0.0001   5     6.1    79    33.6   0.05   0.0001

                           Triple negative        12                           17.6   23    16.3                 0.29                        0.034    10    12.2   30    12.8   0.28   0.005

                           Non luminal            4                            5.9    28    19.9                 0.08                        0.0001   3     3.6    37    15.7   0.07   0.0001
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Statistical analysis was carried out using Statistica13 software. The qualitative features were presented as the percentage of their occurrence and evaluated with Fisher's test and the c^2^ test with Yates' correction. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated as measures of association between the analysed factors and the presence of *NOD2* mutation. The differences were considered significant if the *p*-value was \< 0.05.

Results {#S3}
=======

The median age at BC diagnosis for the carriers of the *NOD2* mutation was 51.4 years (range, 25.5--80.7 years) and 53.2 years (range, 26.4--78.3 years) for the control group. A total of 209 patients were aged under 50 years: 68 (45.3%) were *NOD2*-mutation carriers and 141 (37.2%) were in the control group.

Group of patients aged ≥ 50 years {#S3_1}
---------------------------------

In the group of patients ≥ 50 years old, a family history of cancer, including BC, was observed more often in *NOD2*-mutation carriers compared with the control group of patients (65% vs. 52%; OR = 1.66; *p* = 0.072, with family history of BC vs. no family history of BC; 32% vs. 15%; OR = 2.65; *p* = 0.002). There were no differences between the control group and *NOD2*-mutation carriers at age ≥ 50 years, in those with a family history of other cancer types.

In the group aged ≥ 50 years, lower tumour size (T1--T2) was observed more often in *NOD2*-mutation carriers compared with the control group (94% vs. 82%; OR = 3.35; *p* = 0.011). Similarly, in patients aged ≥ 50 years, lymph nodes without metastases were reported insignificantly more frequently in *NOD2*-mutation carriers (67% vs. 58%, OR = 1.48, *p* = 0.182). Conversely, histological grade G3 tumours (17% vs. 30%, OR = 0.49, *p* = 0.036) and HER overexpression (10% vs. 49%, OR = 0.11, *p* = 0.0001) were present significantly less often in *NOD2-*mutation carriers. There was also a significant difference between *NOD2*-mutation carriers and the control group according to ER-- (16% vs. 32%; OR = 0.39; *p* = 0.007) and PR-- (23% vs. 43%; OR = 0.41; *p* = 0.003) negative steroid receptor status in the group of ≥ 50 years. In the study group, there was no notable difference between *NOD2*-mutation carriers and the control group, according to the BC histological type ([Table 3](#T3){ref-type="table"}).

Group of patients aged \< 50 years {#S3_2}
----------------------------------

In the group of patients \< 50 years old, there was no difference observed between *NOD2-*mutation carriers and the control group, according to those with a family history of cancer (60% vs. 59%; OR = 1.06; *p* = 0.963), particularly those with a family history of BC (25% vs. 19%; OR = 1.41; *p* = 0.429). Conversely, history of colorectal cancer was observed significantly more often in younger *NOD2*-mutation carriers compared with the control group (15% vs. 6%; OR = 2.87; *p* = 0.037). A similar tendency was reported in those with a family history of pancreatic cancer (5.9% vs. 1.4%; OR = 4.34; *p* = 0.089). There were no differences between younger patients and the control group, based on a family history of stomach cancer (8.8% vs. 8.5%; OR = 1.04; *p* = 0.851). Similar results were reported in those with a family history of lung cancer (8.8% vs. 9.2%; OR = 0.95; *p* = 0.870) or gynaecological cancer (10.3% vs. 8.5%; OR = 1.23; *p* = 0.870) ([Table 2](#T2){ref-type="table"}).

There was no difference between younger *NOD2-*mutation carriers and the control group, according to tumour size (T1--T2) (84% vs. 82%; OR = 1.12; *p* = 0.934). Lymph nodes without metastases (63% vs. 47%; OR = 1.95; *p* = 0.038) were significantly more frequently observed in *NOD2*-mutation carriers compared with the control group at this age. In the group of individuals of \< 50 years old, histological grade G3 was non-significantly more often observed in *NOD2-*mutation carriers (*p* = 0.658). Conversely, HER2 overexpression was reported significantly less often in *NOD2*-mutation carriers (22% vs. 54%; OR = 0.24; *p* = 0.0001) at this age. There was a significant difference between *NOD2*-mutation carriers and the control group, according to ER-- (24% vs. 38%; OR = 0.50; *p* = 0.049) negative steroid receptor status, while there was no differences for PR-- (31% vs. 40%; OR = 0.68; *p* = 0.277) negative steroid receptor status. Conversely, there was no difference between *NOD2-*mutation carriers and the control group, according to BC histological type -- ductal invasive carcinoma (79% vs. 78%) in the group of individuals \< 50 years ([Table 3](#T3){ref-type="table"}).

Breast cancer molecular subtypes {#S3_3}
--------------------------------

The presence of BC molecular subtypes in *NOD2*-mutation carriers and in the control group of patients differ from each other significantly (*p* = 0.0001). This is due to the differences in the presence of HER2 overexpression, positive oestrogen (ER+), and progesterone (PR+) steroid receptor status in both groups (*NOD2*-mutation carriers and the control group). The most commonly observed BC subtypes in the present study among *NOD2-*mutation carriers were luminal A and luminal B HER2(--). These subtypes were observed in 60% of younger *NOD2*-mutation carriers (\< 50 years) and in 78% of *NOD2*-mutation carriers over 50 years of age (*p* = 0.018). In the group \< 50 years of age, luminal A (26% vs. 7%) and luminal B HER2(--) (34% vs. 23%) BC subtypes were reported more frequently in patients with *NOD2* mutation compared with the control group ([Fig. 1](#F1){ref-type="fig"}). Similarly, in the group of individuals ≥ 50 years old, luminal A (49% vs. 15%) and luminal B HER2(--) (29% vs. 23%) subtypes were reported more often in patients with *NOD2* mutation ([Fig. 2](#F2){ref-type="fig"}). The risk of the presence of other BC subtypes than luminal A among *NOD2*-mutation carriers is lower compared with the control group, independently of patients' age ([Table 3](#T3){ref-type="table"}).

![Breast cancer molecular subtypes in group of patients aged \< 50 years](WO-24-97475-g001){#F1}

![Breast cancer molecular subtypes in group of patients aged ≥ 50 years](WO-24-97475-g002){#F2}

Logistic regression analysis results {#S3_4}
------------------------------------

Factors that were significantly associated with the presence of *NOD2* mutation among BC subgroups, in patients aged ≥ 50 years and \< 50 years, were detected. Patients ≥ 50 years of age were characterised by lower tumour size (T1--T2), lower histological grade (G1--G2), positive steroid receptor status (ER+ and PR+), and tumours without HER2 overexpression. Conversely, younger (\< 50 years) *NOD2*-mutation carriers were characterised by the deficiency of lymph node metastases (N0), ER+ status, and tumours without HER2 overexpression ([Table 3](#T3){ref-type="table"}).

Multivariate logistic regression analysis results for *NOD2* mutation among patients with BC is shown in [Table 4](#T4){ref-type="table"}. Among patients with BC at the age ≥ 50 years, the presence of *NOD2* mutation was significantly associated with lack of HER2 overexpression (OR = 0.12; *p* = 0.0001), lower tumour size (T; OR = 0.35; *p* = 0.041), and ER+ status (OR = 2.03; *p* = 0.046). However, among patients with BC below the age of 50 years the presence of *NOD2* mutation was significantly associated with HER2-negative status (OR = 0.25; *p* = 0.0001) and insignificantly with ER-positive status (OR = 1.94; *p* = 0.058).

###### 

Univariate and multivariate logistic regression

  Characteristics                          Univariate analysis               Multivariate analysis                                           
  ---------------------------------------- --------------------------------- ----------------------- ------------------- ------------------- --------
  Age ≥ 50 years vs. \< 50 years           0.72 (0.49--1.06)                 0.098                   0.61 (0.40--0.93)   0.020               
  Status: post- vs. premenopausal          0.76 (0.52--1.11)                 0.158                                                           
  T3--T4 vs. T1--T2                        0.55 (0.31--0.99)                 0.044                                                           
  N+ vs. N0                                0.62 (0.42--0.91)                 0.016                                                           
  G3 vs. G1--G2                            0.80 (0.53--1.22)                 0.304                                                           
  ER+ vs. ER0                              2.20 (1.40--3.48)                 0.001                   2.10 (1.30--3.41)   0.003               
  PR+ vs. PR0                              1.95 (1.29--2.96)                 0.002                                                           
  HER2 positive vs. HER2 negative          0.17 (0.11--0.28)                 0.0001                  0.17 (0.11--0.28)   0.0001              
  Breast cancer patients age \< 50 years                                                                                                     
                                           T3--T4 vs. T1--T2                 0.90 (0.41--1.95)       0.934                                   
                                           N+ vs. N0                         0.51 (0.28--0.93)       0.038                                   
                                           G3 vs. G1--G2                     1.20 (0.66--2.17)       0.658                                   
                                           ER+ vs. ER0                       2.02 (1.05--3.88)       0.049               1.94 (0.98--3.83)   0.058
                                           PR+ vs. PR0                       1.47 (0.80--2.73)       0.277                                   
                                           HER2 positive vs. HER2 negative   0.24 (0.12--0.47)       0.0001              0.25 (0.13--0.48)   0.0001
  Breast cancer patients: age ≥ 50 years                                                                                                     
                                           T3--T4 vs. T1--T2                 0.30 (0.11--0.78)       0.011               0.35 (0.13--0.96)   0.041
                                           N+ vs. N0                         0.67 (0.40--1.14)       0.182                                   
                                           G3 vs. G1--G2                     0.49 (0.26--0.92)       0.036                                   
                                           ER+ vs. ER0                       2.54 (1.32--4.87)       0.007               2.03 (1.01--4.08)   0.046
                                           PR+ vs. PR0                       2.46 (1.38--4.36)       0.003                                   
                                           HER2 positive vs. HER2 negative   0.11 (0.05--0.24)       0.0001              0.12 (0.05--0.26)   0.0001

Multivariate analysis has shown, for all study groups, that the older age (OR = 0.61; *p* = 0.020), ER+ status (OR = 2.10; *p* = 0.003), and tumours without HER2 overexpression (OR = 0.17; *p* = 0.0001) were risk factors for *NOD2* mutation in patients with BC ([Table 4](#T4){ref-type="table"}).

*NOD2*-mutation carriers at the age of \< 50 years vs. ≥ 50 years {#S3_5}
-----------------------------------------------------------------

The comparison of patients with *NOD* mutations in age groups \< 50 and ≥ 50 years indicated a tendency towards higher incidence of negative factors in the group of younger patients with BC ([Table 5](#T5){ref-type="table"}). BC tumours with G3 (40% vs. 17%; OR = 3.20; *p* = 0.004) and with HER2 overexpression (22% vs. 10%; OR = 2.62; *p* = 0.043) were observed significantly more often among younger patients with *NOD2* mutation. The tendency towards the presence of larger tumour size (T3--T4) in younger *NOD2*-mutation carriers was also observed.

###### 

Pathological characteristics of the tumours in breast cancer patients with *NOD2* mutation according to age

  ------------------------------------------------------------------------------------------------------------------------------------
  Risk factor              *NOD2* \< 50 years\    *NOD2* ≥ 50 years\   *NOD2*\                             *p*                 
                           (*n* = 68)             (*n* = 82)           \< 50 years vs. *NOD2* ≥ 50 years                       
  ------------------------ ---------------------- -------------------- ----------------------------------- ----- ------ ------ -------
  Clinical staging nodes                                                                                                       

                           N positive             25                   36.8                                27    32.9   1.18   0.749

                           N negative             43                   63.2                                55    67.1   1      

  Tumour size                                                                                                                  

                           T3--4                  11                   16.2                                5     6.1    2.97   0.063

                           T1--2                  57                   83.8                                77    93.9   1      

  Grade G                                                                                                                      

                           G3                     27                   39.7                                14    17.1   3.20   0.004

                           G1 + G2                41                   60.3                                68    82.9   1      

  ER                                                                                                                           

                           Negative               16                   23.5                                13    15.9   1.63   0.328

                           Positive               52                   76.5                                69    84.1   1      

  PR                                                                                                                           

                           Negative               21                   30.9                                19    23.2   1.48   0.380

                           Positive               47                   69.1                                63    76.8   1      

  HER2 overexpression                                                                                                          

                           Positive               15                   22.1                                8     9.8    2.62   0.043

                           Negative               53                   77.9                                74    90.2   1      

  Molecular subtype                                                                                                            

                           Luminal A & B-- type   41                   60.3                                64    78.0   0.43   0.029

                           Others                 27                   39.7                                18    22.0   1      

  Triple negative                                                                                                              

                           Yes                    12                   17.6                                10    12.2   1.54   0.479

                           No                     56                   82.4                                72    87.8   1      

  Molecular subtype                                                                                                            

                           Luminal A type         18                   26.5                                40    48.8   1      

                           Luminal B-- type       23                   33.8                                24    29.3   2.13   0.095

                           Luminal B+ type        11                   16.2                                5     6.1    4.89   0.009

                           Triple negative        12                   17.6                                10    12.2   2.67   0.093

                           Non luminal            4                    5.9                                 3     3.7    2.96   0.215
  ------------------------------------------------------------------------------------------------------------------------------------

Multivariate analysis of pathological factors in the group of individuals with *NOD2* mutation has shown that only G3 (OR = 3.22; *p* = 0.003) was significantly associated with the presence of *NOD2* mutation in younger patients.

Discussion {#S4}
==========

In the present study, *NOD2*-mutation carriers at age ≥ 50 years were compared with the control group and with the younger (\< 50 years) subgroup of patients with *NOD2* mutation; according to the clinicopathological factors, such as hormone status ER, PR, HER2, tumour size, the presence of lymph node metastases, and history of cancer in the family.

The insignificant association between the *NOD*2 3020insC mutation and a family history of BC was reported by Huzarski *et al*. \[[@ref5]\]. The 3020insC mutation of the *NOD2/CARD15* gene may also be a genetic predisposing factor for aggregations of breast and lung cancer. Lener *et al*. reported that the presence of *NOD2* mutation was higher in patients with BC who had a first- or second-degree relative diagnosed with lung cancer compared with patients who had no relatives affected by lung cancer \[[@ref11]\]. Janiszewska *et al*. \[[@ref8]\] suggested that the *NOD2* 3020insC mutation may increase the risk of developing gastrointestinal cancer rather than BC. Similarly, in a study conducted by Kurzawski *et al*., the frequency of the 3020insC mutation in 250 patients with non-hereditary nonpolyposis colorectal cancer at age \>50 years was significantly higher in comparison to the control group (OR, 2.23; *p* = 0.0046) \[[@ref9]\]. In another study, the risk of gastric cancer in *NOD2* 3020insC-mutation carriers at age \>50 years was more than doubled (OR = 2.479; *p* = 0.022) and was almost even three-fold greater among women \[[@ref10]\]. In a previous analysis, the presence of *NOD2* mutation was associated with an increased risk of a family history of breast, renal, and colorectal cancer \[[@ref7]\]. In the present analysis, a family history of cancer, including BC, was observed more often in *NOD2*-mutation compared with the control group; in patients at age ≥ 50 years. In the group of patients at age \< 50 years, the presence of cancer in family history was similar between *NOD2*-mutation carriers and the control group. Conversely, a family history of colorectal and pancreatic cancer was observed significantly more often in younger *NOD2*-mutation carriers compared with the control group.

The association between *NOD2* mutation and clinicopathological factors in cancer was described only in a few data \[[@ref7], [@ref12]\]. Lakatos *et al*. conducted a study on patients with colorectal cancer and reported no association between clinicopathological factors (such as patient's age or symptoms at diagnosis) and the *CARD15*/*NOD2* variants carrier status \[[@ref12]\]. In a previous analysis, no differences between *NOD2* (3020insC) mutation carriers and non-carriers were reported, according to co-morbid condition, drugs, tumour size, steroid receptor status, and five-year overall survival. *NOD2* mutation in women with BC was characterised by lymph nodes without metastasis (N0), lower histological grade (G\<3), and negative HER2 receptor status (HER2--) \[[@ref7]\].

In the present analysis, the subgroup of BC *NOD2*-mutation carriers at age ≥ 50 years was characterised by lower tumour size (T1--T2), lower histological grade (G1--G2), positive steroid receptor status (ER+ and PR+), and tumours without HER2 overexpression. Patients at age \< 50 years are characterised by lymph nodes without metastases, ER+ status, and tumours without HER2 overexpression. There was no difference between *NOD2*-mutation carriers and the control group observed, according to the BC histological type.

ER+ status and tumours without HER2 overexpression were mostly characteristic of patients with BC with *NOD2* mutation, independently of age, in comparison to the control group. Multivariate logistic regression has improved these results and has showed that patients at age ≥ 50 years have a lower risk of *NOD2* mutation compared with the younger age group (OR = 0.61; *p* = 0.020).

In the group of patients with *NOD2* mutation at age ≥ 50 years, histological grades G3 and HER overexpression were observed significantly less often compared with younger *NOD2-*mutation carriers.

Luminal A and luminal B HER2 BC subtypes were most characteristic of patients with *NOD2* mutation, independently of age. This analysis was conducted on a larger group of patients, in comparison to the previous study.

The present study has potential limitations. The most important limitation is the group size. Due to some differences between the previous and present studies, a larger group of patients is required. HER2-negative status was characteristic of patients with BC with *NOD2* mutation, independently of age, compared with the control group, in the previous and present studies. The other factors such as N0 and G1--G2 were reported from univariate analysis in the present study, but in different subgroups. N0 is observed significantly more often in *NOD2*-mutation carriers at age \< 50 years and G1--G2 in the subgroup of individuals at age ≥ 50 years. In a previous study, patients without *NOD2* mutation and *NOD2*-mutation carriers had similar ages at diagnosis. This can be the cause of the differences.

Conclusions {#S5}
===========

A family history of BC was characteristic of *NOD2*-mutation carriers at age ≥ 50 years. HER2 overexpression and ER status were significantly associated with the presence of *NOD2* mutation in patients with BC, independently of age. Luminal A or luminal B HER2-negative BC subtypes were most characteristic of patients with *NOD2* mutation, independently of age.

In *NOD2*-mutation carriers at the age ≥ 50 years, the presence of higher tumour size, G3 or HER2 overexpression were lower compared with younger patients. Multivariate analysis has shown that only G significantly differentiates both groups of *NOD2*-mutation carriers.
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